Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Aspirin 150mg.paracetamol 250mg.caffeine 30mg

Clinical medicine profile

Aspirin 150mg.paracetamol 250mg.caffeine 30mg

Non-opioid analgesic / antipyretic

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
ORAL / RECTAL / IV
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Severe active hepatic disease / acute liver failure.
  • Hypersensitivity.
  • Chronic heavy alcohol use — use reduced maximum daily dose or avoid.

Precautions

  • Do not exceed 4 g/day in adults (lower in malnutrition, alcohol, elderly, liver disease — often ≤2–3 g).
  • Account for combination products (cold remedies).
  • Overdose is a medical emergency (NAC protocol).
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Generally safe; prolonged high dose rare associations — prefer careful use in advanced CKD.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

PRIMARY toxicity organ in overdose; therapeutic doses usually safe if daily limits respected.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Non-opioid analgesic / antipyretic).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.

Adverse effects

  • Rare at therapeutic doses.
  • Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP).
  • First-line for mild–moderate pain and fever.
  • Calculate total daily exposure from all sources.
  • In overdose: timed levels + NAC per protocol — do not wait for symptoms.
04 Pharmacology

Mechanism & disposition

Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways.

Inhibit COX↓ ProstaglandinsAnalgesia / anti-inflammatory
Read complete mechanism

Paracetamol inhibits central prostaglandin synthesis via effects on cyclo-oxygenase pathways (including COX-2 preferential central effects) and may engage serotonergic descending pathways. Antipyretic effect via hypothalamic heat-regulating centre. Minimal peripheral anti-inflammatory action.

Onset

30–60 minutes oral

Duration

4–6 hours

Route

ORAL / RECTAL / IV

Metabolism

(glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted.

Half-life

~2–3 h; prolonged in liver disease/overdose.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration.

Lactation

Compatible with breastfeeding at standard doses.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceUnsourced template; Local active-ingredient clinical extract; Professional class pharmacology (Non-opioid analgesic / antipyretic)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.